Orphan Drug Marketing
Locating physicians that treat patients who would benefit from your orphan drug can be a costly, “needle-in-a-haystack” type of endeavor. The Schwartz Group can limit the costs and streamline the process of reaching and detailing targeted physicians in an effort to change prescribing habits. We have successfully partnered with leading orphan drug companies to engage physicians and uncover new opportunities for our clients’ therapies.
HIGHLY-TARGETED, CUSTOMIZED CAMPAIGNS
We work on a daily basis with our clients to ensure the success of every campaign. Working closely with your field sales force and regulatory department, we implement proven approaches to locating prospective opportunities and make refinements in consultation with our clients whenever needed. Our orphan drug marketing campaigns are therefore highly-collaborative and individually-optimized to locate and identify potential consumers, producing measurable returns on investment for our partners.
We believe the success of every campaign depends on collaborative and responsive partnership. Our internal efficiency allows us to make instant changes to the strategic focus of any campaign based on the direction we receive from our client.
Case Study
Rare metabolic disease
Global biopharmaceutical company focused on acquiring and developing treatments for patients with rare diseases
Identify new opportunities for treatment of rare metabolic disorder
A two-pronged Schwartz Inside Partnering (SIP) program executed in separate phases of marketing intelligence-gathering and lead generation
Phase I: Market Intelligence-Gathering
- Using 2 Schwartz Inside Partners (SIPs) over a twelve-month period, TSG was able to generate 20,395 requests of informative material regarding the disease state & treatment options, in addition to identifying 210 physicians managing patient(s) with a rare metabolic disease.
In addition to identifying providers managing patients with this condition, TSG was able to confirm 895 physicians that are not seeing patients with this disease, creating a comprehensive list of providers not requiring immediate follow-up from sales representatives
Phase II: Lead Generation
- Of the 210 TSG identified physicians treating patients with this rare disease, 58 patients began or converted treatment to our clients’ new product indicated for the conditions’ long-term maintenance
- Each SIP was assigned to nine outside sales representatives to generate leads. Our client was able to ensure territories covered by the Schwartz Inside Partnering program were kept current of all updates regarding the disease state as well as the promotion of treatment resources offered to patients without an existing treatment plan.